Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed an efficient process to rapidly discover new “enediyne natural products” from soil microbes that could be further developed into extremely potent anticancer drugs.
The study highlights microbial natural products as abundant sources of new drug leads. The researchers’ discovery process involves prioritizing the microbes from the TSRI strain collection and focusing on the ones that are genetically predisposed to produce specific families of natural products. The scientists say this process saves time and resources in comparison to the traditional approaches used to identify these rare molecules.
The study, led by TSRI Professor Ben Shen, was published today in the journal mBio.
Shen and his colleagues uncovered a new family of enediyne natural products, called tiancimycins, (TNMs) which kill selected cancer cells more rapidly and completely in comparison to toxic molecules used in FDA-approved antibody-drug conjugates (ADCs)— monoclonal antibodies attached to cytotoxic drugs that target only cancer cells.
The scientists also discovered several new producers of C-1027, an antitumor antibiotic currently in clinical development, which can produce C-1027 at much higher levels.
It has been more than a decade since Shen first reported on the C-1027 enediyne biosynthetic machinery, and he speculated then that the knowledge obtained from studying biosynthesis of C-1027, and other enediynes, could be used for the discovery of novel enediyne natural products.
“The enediynes represent one of the most fascinating families of natural products for their extraordinary biological activities,” Shen said. “By surveying 3,400 strains from the TSRI collection, we were able to identify 81 strains that harbor genes encoding enediynes. With what we know, we can predict novel structural insights that can be exploited to radically accelerate enediyne-based drug discovery and development.”
“The work described by the Shen group is an excellent example of what can be achieved by coupling state of the art genomic analyses of potential biosynthetic clusters and modern physicochemical techniques,” said David J. Newman, retired chief of the National Cancer Institute’s Natural Products Branch. “As a result of their work, the potential number of enediynes has significantly increased.”
Shen’s method of strain prioritization and genome mining means a far more efficient use of resources involved in the discovery process, targeting only those strains that look to produce the most important natural compounds.
“This study shows that the potential to rapidly discover new enediyne natural products from a large strain collection is within our reach,” said TSRI Research Associate Xiaohui Yan, one of four first authors of the study. “We also show the feasibility of manipulating tiancimycin biosynthesis in vivo, which means that sufficient quantities of these precious natural products can be reliably produced by microbial fermentation for drug development and eventual commercialization.”
Receive an email update when we add a new ANTI-CANCER DRUG article.
The Latest on: Anticancer drug
via Google News
The Latest on: Anticancer drug
- New Drug Screening Tool for Cancer Research Comes to Marketon September 6, 2019 at 11:49 am
Sanatela’s bioengineering process produces a 3D structure with all the components needed for expanding and maintaining stem cells, making it the ideal natural environment for screening chemotherapy ...
- In Vitro and In Vivo Evaluation of the Anticancer and Anti-inflammatory Activities of 2-Himachelen-7-ol isolated from Cedrus Libanion September 6, 2019 at 2:19 am
Among the current anticancer medications, more than 60% of drugs approved for cancer treatment between 1940 and 2002 have either been natural products or formulations based on natural products; a rate ...
- Drug Delivery in Cancer, 2019: Technologies, Markets & 238 Companies - Global Forecast to 2028on September 6, 2019 at 1:20 am
The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent damage to normal tissues and prevent drug resistance. Innovative cancer ...
- New drug may enhance efficacy of chemotherapy in pancreatic canceron September 5, 2019 at 12:45 am
One of the major obstacles in the treatment of pancreatic cancer is the 'defense wall' that is formed around the tumor. This 'desmoplastic stroma' prevents chemotherapy from reaching the tumor.
- Superbugs Deadlier Than Cancer Put Chemotherapy Into Questionon September 4, 2019 at 9:01 pm
In India, some 1.7 million receive a cancer diagnosis every year, often leading to chemotherapy that makes them especially vulnerable. Worldwide, at least 700,000 people die annually from ...
- Global Chemotherapy Drugs Market Estimated to Rising at a Lucrative CAGR of +11.91% Regional Trends and Comprehensive Research Study 2024on September 4, 2019 at 5:05 am
Sep 04, 2019 (AmericaNewsHour) -- A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report ...
- Pancreatic cancer tumors attack the blood vessels that deliver chemo drugson September 4, 2019 at 4:12 am
Pancreatic cancer is nearly impossible to treat. New research now shows this may be because its tumors destroy the surrounding blood vessels that doctors typically rely on to deliver anti-cancer drugs ...
- Lupin, Boehringer Ingelheim ink $700m licensing deal for anti-cancer drugon September 4, 2019 at 3:26 am
The drug is expected to take around five-to-seven years to be commercialised. Lupin will receive an upfront payment of $20 million Lupin, India's third largest drug maker, on September 4 has entered ...
- FAK protein linked to chemotherapy resistance in ovarian canceron September 4, 2019 at 12:07 am
"We know that a subpopulation of stem-like cancer cells can survive chemotherapy and lead to recurrence, drug resistance and even death," said Schlaepfer. "These findings suggest FAK is an ...
via Bing News